Escolar Documentos
Profissional Documentos
Cultura Documentos
Uma Shankar Agarwal, Raj Kumar Besarwal, Kalyani Bhola Department of Dermatology, SMS Medical Collage and Hospital Jaipur, Rajasthan, India
Indian Journal of Dermatology, Venereology, and Leprology Year 2011 Volume 77 Issue 6
Ditandai dengan komedo, papul,pustul, nodul, kista,abses,dan terkadang jaringan sikatris yang luas
Umumnya dimulai pada usia remaja dan membaik pada usia pertengahan 20 tahun
Derajat Keparahan
Topical
Sistemic
Antibiotik
Isotretinoin
Untuk membandingkan efek dan toleransi dari bermacam regimen (harian, alternate, pulse, dan dosis rendah), dilakukan uji prospektif ini
Efek samping
Diberikan 0.51mg/kgbb/hari pc pada acne nodulocystic berat, hingga dosis kumulatif 120150mg/kgbb
Dosis rendah
Mungkin dapat efektif dalam menurunkan efek samping dan biaya, maka dapat digunakan regimen lain dibanding dosis umum harian
Dosis
harian
alternate
pulse
dosis rendah
Include
120 penderita acne vulgaris
Exclude
Informed consent
Rekam Medis
Ringan
Sedikit hingga beberapa papul/pustul Tanpa nodul Beberapa hingga banyak papul/pustul Sedikitbeberapa nodul
Sedang
Berat
Komedo non inflamasi, terbuka dan tertutup (tanpa eritema) 0.5 Komedo/Papul dikelilingi eritema -1
APABILA
TG > 400mg/dl AP > 264 U/L(wanita) >500 U/L (pria) AST >80U/L cholesterol >300mg/dl ALT >62U/L
STOP!
I S O T R E T I N O I N
Grup A 1mg/kgbb/hari
Oral Azitromycin 1x500mg a.c selama 3 hari dalam seminggu selama 3 minggu
Perbaikan lesi dicatat dengan menghitung Total Acne Load saat followup
Dosis rendah hampir sama efeknya dengan dosis tinggi, namun efek samping dan biayanya minimal
Untuk acne berat, bisa dengan dosis tinggi pada umumnya atau dengan dosis tinggi untuk 8minggu awal dan diturunkan menjadi dosis rendah
Dipertimbangkan pada acne ringan dan sedang dalam dosis rendah dan alternate, karena efektivitas dan keamanan
1.Dreno B, Poli F. Epidemiology of acne. Dermatology 2003;43:1042-8. 2.Kaymak Y, Ilter N. The effectiveness of intermittent isotretinoin treatment in mild or moderate acne. J Eur Acad Dermatol Venereol 2006;20:1256-60. [PUBMED] [FULLTEXT] 3.Harper JC, Thibutot DM. Pathogenesis of acne: Recent research advances. Adv Dermatol 2003;19:1-10. 4.Cunliffe W, Gollnick H. Acne. In: Arndt KA, LeBoit PE, Robinson JK, Wintroub BU, editors. Cutaneous Medicine and Surgery. Philadelphia, Pa: WB Saunders Co; 1996. p. 461-80. 5.Pochi PE, Shalita AR, Strauss JS, Webster SB, Cunliffe WJ, Katz HI, et al. Report of the consensus conference on acne classification. J Am Acad Dermatol 1991;24:495-500. [PUBMED] 6.Liden S, Goransson K, Odsell L. Clinical evaluation in acne. Acta Dermato Venereol Suppl (Stockh) 1980;89:47-52. 7.Akman A, Durusoy C, Senturk M, Koc CK, Soyturk D, Alpossy E. Treatment of acne with intermittent and conventional isotretinoin: A randomised controlled multicenter study. Arch Dermatol Res 2007;299:467-73. 8.Culniffe WJ, van de Kerkhof PC, Caputo R, Cavicchini S, Cooper A, Fyrand OL, et al. Roaccutane treatment guidelines: results of an international survey. Dermatology 1997;194:351-7. 9.Peck GL, Olsen TG, Yoder FW, Downing DT, Pandya M, et al. Prolonged remissions of cystic and conglobate acne with 13-cisretinoic acid. N Engl J Med 1979;300:329-33. [PUBMED] [FULLTEXT] 10.Farrell LN, Strauss JS, Stranieri AM. The treatment of severe cystic acne with 13-cis-retinoic acid. Evaluation of sebum production and the clinical response in a multiple-dose trial. J Am Acad Dermatol 1980;3:602-11. [PUBMED] 11.Bellosta M, Vignini M, Miori L, Rabbiosi G. Low-dose isotretinoin in severe acne. Int J Tissue React 1987;9:443-6. [PUBMED] 12.Goulden V, Clark SM, Cunliffe WJ. Post adolescent acne: A review of clinical features. Br J Dermatol 1997;136:6670. [PUBMED] 13.Hermes B, Praetel C, Henz BM. Medium dose isotretinoin for the treatment of acne. J Eur Acad Dermatol Venereol 1998;11:117-21. [PUBMED] 14.Geissler SE, Michelsen S, Plewig G. Very low dose isotretinoin is effective in controlling seborrhoea. J Dtsch Dermatol Ges 2003;1:952-8. [PUBMED] [FULLTEXT] 15.Amichai B. Long term mini doses of isotretinoin in the treatment of relapsing acne. J Dermatol 2003;30:572. [PUBMED] [FULLTEXT] 16.Sardana K, Garg VK, Sehgal VN, Mahajan S, Bhushan P. Efficacy of fixed low-dose isotretinoin (20 mg, alternate days) with topical clindamycin gel in moderately severe acne vulgaris. J Eur Acad Dermatol Venereol 2009;23:556-60. [PUBMED] [FULLTEXT] 17.Mandekou- Lefaki I, Delli F, Teknetzis A, Euthimiadou R, Karakatsanis G. Low dose schema of isotrinoin in acne vulgaris. Int J Clinical Pharmacol Res 2003;23:41-6. 18.Sardana K, Garg VK. Efficacy of low dose of isotretinoin in acne vulgaris. Indian J Dermatol Venereol Leprol 2010;77:7-13. 19.Strauss JS, Leyden JJ, Lucky AW, Lookingbill DP, Drake LA, Hanifin JM, et al. A randomized trial of the efficacy of a new micronized formulation versus a standard formulation of isotretinoin in patients with severe recalcitrant nodular acne. J Am Acad Dermatol 2001;45:187-95. [PUBMED] [FULLTEXT] 20.Amichai B, Shemer A, Grunwald MH. Low-dose isotretinoin in the treatment of acne vulgaris. J Am Acad Dermatol 2006;54:644-6. [PUBMED] [FULLTEXT] 21.Palmer RA, Sidhu S, Goodwin PG. 'Microdose' isotretinoin. Br J Dermatol 2000;143:205-6. [PUBMED] [FULLTEXT] 22.Sardana K, Sehgal VN. Retinoids: Fascinating up-and-coming scenario. J Dermatol 2003;30:355-80. [PUBMED] [FULLTEXT] 23.Ross JI, Snelling AM, Carnegie E, Coates P, Cunliffe WJ, Bettoli V, et al. Antibiotic-resistant acne: Lessons from Europe. Br J Dermatol 2003;148:467-78. [PUBMED] [FULLTEXT] 24.Rafiei R, Yaghoobi R. Azithromycin versus tetracycline in the treatment of acne vulgaris. J Dermatolog Treat 2006;17:217-21. [PUBMED] [FULLTEXT]